Peripheral neurological manifestations have been reported following Coronavirus disease 2019 (COVID-19) infection, whereas neuropathic symptoms after COVID-19 vaccination remain less well characterized. To evaluate self-reported neuropathic symptoms following COVID-19 vaccination and identify factors associated with postvaccination symptom reporting, while accounting for previous confirmed COVID-19 infection. This cross-sectional survey included adults recruited from university-affiliated settings. Data were collected using a structured English/Arabic questionnaire covering COVID-19 infection, vaccination history, comorbidities, medication use, and neuropathic symptoms, including tingling, numbness, burning sensation, and electric shock–like sensations. Participants who reported symptoms were invited for neurological clinical assessment. The primary outcome was self-reported neuropathic symptoms potentially suggestive of peripheral neuropathy following COVID-19 vaccination. Previous confirmed COVID-19 infection was treated as a potential confounder in multivariable analysis. A total of 1201 individuals were screened, of whom 1166 were included in the final analysis. Postvaccination self-reported neuropathic symptoms were reported by 472 of 1090 vaccinated participants (43.3%). Following the first vaccine dose, symptom reporting differed significantly by vaccine type ( P < .001), with the highest proportions observed among recipients of Oxford-AstraZeneca COVID-19 vaccine (190/316 [60.1%]) and Sputnik V COVID-19 vaccine (37/92 [40.2%]). In multivariable analysis, older age, use of medications with reported or potential associations with peripheral neuropathy, and receipt of ChAdOx1-S, Gam-COVID-Vac, or Sinovac-CoronaVac were associated with increased post-vaccination symptom reporting ( P < .05), whereas previous confirmed COVID-19 infection was not independently associated with the outcome. In exploratory booster-dose analysis, homologous booster vaccination was associated with lower odds of symptom reporting than heterologous boosting (adjusted odds ratio 0.38, P < .001). Self-reported neuropathic symptoms were frequently reported following COVID-19 vaccination and varied according to vaccine type. Older age, selected vaccine types, and heterologous booster schedules were associated with symptom reporting. These findings are hypothesis-generating and should be interpreted cautiously because they reflect self-reported symptoms rather than confirmed peripheral neuropathy diagnoses and were not routinely confirmed by objective neurological investigations.